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Superficial venous hypertension has been cited as the putative etiologic factor in advanced chronic venous insufficiency
with venous ulcer (CEAP C 5/6). For over a century, influenced by this belief, surgeons have ablated the superficial
venous system as a treatment for venous ulcer. Incompetent perforating veins (ICPVs) have become a particular focus of
this therapeutic strategy. This review examines the evidence for the surgical approach. A MEDLINE search of the
literature identified only four randomized controlled trials (RCTs) directed at the surgical reduction of superficial venous
hypertension. Risk ratios for ulcer healing and prevention of recurrence were calculated to determine benefits for these
four RCTs, while mortality and morbidity, where available, was used to determine risk from the procedure. In addition,
the quality of the trials (design and outcomes) was assessed. While two trials compared ICPV ligation to compression, the
great saphenous vein (GSV) was also treated in many of these limbs, which confounds the results. By contrast, two RCTs,
which compared treatment of the GSV alone to compression, demonstrated a significant reduction in the incidence of
ulcer recurrence. Case series that employed hemodynamic or surrogate outcomes showed little effect on the addition of
ICPV treatment to GSV stripping, while GSV ablation alone was associated with a reduction in the number of ICPVs in
several studies. This review suggests a grade 1A recommendation for the treatment of venous ulcer by GSV ablation to
reduce ulcer recurrence. The role of ICPV ablation alone or concomitant with GSV treatment awaits results of properly
conducted RCTs. (J Vasc Surg 2008;48:1044-52.)Reduction of venous hypertension by surgical ablation
of the incompetent superficial venous system (great saphe-
nous vein [GSV], small saphenous vein [SSV], branch
tributaries and perforators) has been a fundamental ap-
proach to the treatment of venous ulcer for nearly a cen-
tury.1 Incompetent perforating veins (ICPVs) in particular
have been cited frequently as an important etiologic factor
in the pathogenesis of venous ulcer and the focal point for
therapy.2 Therefore, the interruption of ICPVs by subfas-
cial endoscopic perforator surgery (SEPS) has been recom-
mended as an essential element in the reduction of super-
ficial hypertension and the “cure” of venous ulcer.3 What is
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1044the supporting data for this belief and how valid is it?
Evidence-based medicine is a helpful tool to the clinician
for assessing the optimal treatment, based on the best
available current knowledge.4 This method has provided a
way to analyze the statistical strength or “quality” of vari-
ous studies, which supports a treatment choice and allows
the clinician to assess the bias and strength of evidence
surrounding that therapeutic recommendation. Evidence-
based medicine has evolved from merely an assessment of
study(s) qualities to combining study strength with an
estimate of the risk to benefit trade off of a particular
therapy in order to make an overall recommendation.5
It is the purpose of this paper to review the evidence for
treating the superficial venous system, especially the perfo-
rators, in advanced chronic venous insufficiency (CVI)
(CEAP C5/6) by performing a systematic review. Treat-
ment risk will be derived from the interventions mortality
and morbidity (requirement for hospitalization) while the
promotion of ulcer healing and/or reduction in ulcer re-
currence will represent the benefit. This review will assess
the few randomized controlled trials (RCTs), which ex-
plore the effect of superficial venous surgery on the clinical
outcomes of venous ulcer healing and recurrence. This
ent; IC
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evidence for the treatment of ICPVs. We had performed a
previous systematic review on the efficacy of SEPS in gen-
eral, which covered the period from 1966 through Decem-
ber 2002 and failed to identify any RCTs with ulcer healing
or recurrence as their outcomes.6 The current review was
restricted to the period January 2003 through December
30, 2007. Studies cited in the previous review as well as new
non-RCTs will be incorporated into the discussion of the
current systematic analysis.
METHODS
A MEDLINE search, which employed the search key
terms “venous insufficiency/surgery; varicose ulcer sur-
gery; leg ulcer/surgery”, or the Keyword “perforator” was
performed.6 The search was restricted to human and En-
glish language studies. To be included in this review, the
study had to have the following characteristics: (1) a RCT
study design, (2) a patient population that was restricted to
active and/or healed ulcers (CEAP Clinical Classification
C5/6) and (3) express the study outcome as ulcer recur-
rence. Ulcer healing was a desirable outcome, but not an
essential component for a study to be included in this
review. An analysis of treatment effects was performed on
those trials that met the inclusion criteria by calculating the
risk ratio and the corresponding 95% confidence intervals
from data presented in the original trials. Using desirable
elements of clinical trials as reported by others7 and us8
previously, we assessed the quality of both study design and
Table I. Clinical characteristics of four RCTs
Stacey
(1988)
Number pts/limbs 30/41
Male (%) 57
Age-years (mean) 61
C5 (%) 100
C6(%) 0
Ulcer diameter (mms) —
Ulcer duration (months) —
Previous DVT (%) 50
DVI (%) 50
Diabetes (%) —
Compression type Class? Elastic stocking Dual-
Cla
Surgical RX ICPV/GSV ICPV
Morbidity (%) None reported
Mortality (%) None
Outcome-ulcer (%)
Healing-comp
Healing-surg
Recurr-comp 24
Recurr-surg 5
DVT,Deep venous thrombosis;DVI, deep venous insufficiency;RX, treatm
hemodynamic-based minimally invasive surgery to prevent reflux, but mainoutcomes.RESULTS
Our current systematic review of RCTs for ulcer recur-
rence following treatment of ICPVs revealed 44 reports on
the treatment of ICPVs between 1980 and 2007. From this
review, we identified two level II trials (small subject pop-
ulation)9,10 and two level I trials (large subject popula-
tion),11,12 which satisfied the criteria. In addition, one of
the level I RCTs published a subsequent paper with a
longer follow-up period than its original study.13 Two
RCTs addressed the effect of ICPV treatment on ulcer
healing and recurrence,9,11 while the other two examined
the effect of GSV treatment on the same outcomes.10,12
The characteristics of these four studies are presented in
Table I and will be summarized briefly here.
Putative evidence for the effect of ICPV ligation on
ulcer recurrence. The first RCT by Stacey,9 which in-
cluded 41 limbs with healed venous ulcer, had as its prin-
ciple outcome hemodynamic improvement (calf pump
function), with treatment by either elastic compression
alone or compression and open subfascial ligation (many
limbs also had treatment of the GSV and SSV).9 By foot
volumetry, the half volume refilling time was comparable
between the surgical and compression group, but the ex-
pelled volume was improved significantly in the surgical
group. Ulcer recurrence was not reported in the results
section, but rather in the Patients and Methods section as
treatment failure. Only one ulcer recurred in the surgical
arm, while five developed in the compression alone group.
No statistical analysis was provided for the later clinical
findings. There was no differentiation as to howmany limbs
n Gent
006)
Zamboni
(2003)
Barwell
(2004)
0/200 45/47 500
62 40 42
65 63 73
0 0 32
100 100 68
225 110 m 200
4 — 5
31 0 8
52 0 35
7/17 — 38
short-stretch¡
III
Inelastic bandage
& Aqua cell
Multilayer comp¡
class III
CHIVA GSV
— — Surg¡2.4%
Comp¡2.2%
— — 12 mo¡8%
73 96 76
83 100 82
23 38 34
22 9 15
PV, incompetent perforating veins; GSV, greater saphenous vein; CHIVA,
GSV drainage.Va
(2
17
layer
ss II/
/GSVunderwent concomitant treatment of the superficial system
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hoc analysis.
A very important large RCT (level I), the Dutch ulcer
trial, was based on 200 C6 limbs, which were randomized
into either treatment with elastic compression alone or
SEPS (/GSV treatment) with elastic compression (Ta-
ble I).11 This trial, which putatively focused on the effect of
SEPS on ulcer healing/recurrence, was conducted in 12
centers with the ulcer-free period, as determined by
Kaplan-Meier analysis, the primary outcome. The second-
ary endpoints included ulcer healing, ulcer recurrence,
quality of life (QOL), and cost-effectiveness. The investi-
gators stratified patients into: (1) new or recurrent ulcer;
(2) presence of deep venous reflux; and (3) the specific
center where the treatment (medical or surgical) was car-
ried out. Concomitant superficial venous surgery of the
GSV or SSV was performed in 54% and an additional 40
patients had previous treatment of their GSV so that only
6% of patients apparently had treatment of ICPVs alone.
Thus, it would be impossible to separate the effect of
treating the GSV and ICPVs from treating the ICPVs alone
in this RCT.Over a median follow-up length of 27months,
the ulcer-free period was comparable between the SEPS
group (72%) and the compression group (53%), as were
ulcer recurrence and ulcer healing. The authors conducted
a post-hoc analysis, however, that identified certain factors
in favor of the SEPS arm for ulcer-free survival: (1) ulcers of
less than 4 month’s duration; and (2) medial located ulcer
(also favored earlier healing). Of the stratified factors both
(1) recurrent ulcer and (3) surgery carried out in a special-
ized center favorably influenced ulcer-free survival, while
deep-venous reflux had no influence.
The effect of GSV treatment alone. Zamboni, et
al,10 RCT compared ambulatory conservative management
of varicose veins (CHIVA) (hemodynamic-basedminimally
invasive surgery to prevent reflux, but maintaining GSV
drainage) to compression andwound care in 47C6 limbs of
45 patients. Of the 23 limbs undergoing CHIVA, 16 had
high ligation of the GSV and division of its tributaries.
Seven limbs had ligation of the GSV tributaries only. Direct
treatment of the ICPVs was not carried out. QOL im-
proved in the CHIVA group, while venous filling index,
ejection fraction, and residual volume fraction normalized
postoperatively. Most importantly, ulcer recurrence was
significantly lower in the surgical group (9%) in comparison
to the compression group (38%–P .05). The authors did
not provide a separate analysis of the two surgical groups
and reported the results as a whole, which can lead to
heterogeneity.
In the large multi-center effect of surgery and compres-
sion on healing and recurrence (ESCHAR) Trial ligation
and stripping of the GSV / the SSV and compression
was compared to compression alone and wound care,
where the clinical outcomes of ulcer healing and recurrence
were employed.12 Of the 500 limbs, 68% were class VI and
32% class V. Deep venous reflux was evenly distributed in
both arms—37% vs 38%. Of the 195 limbs in the surgical
arm, 141 underwent treatment of the GSV alone; 27 theSSV alone, and 21 the GSV and SSV combined. Only six
limbs (3.1%) had treatment of the perforators, presumably
as the authors stated in their introduction “reserved for the
few (2-3%) legs with isolated calf perforator incompe-
tence.” There was no statistical significance between the
two treatment arms in ulcer healing –76% in the compres-
sion group and 82% in the compression and surgery group.
On the other hand, there was a two-fold reduction of ulcer
recurrence in the surgical arm (15%) over the compression
alone group (34%). The study clearly showed the superior-
ity of GSV ablation to compression for the prevention of
ulcer recurrence.
The risk reduction of the risk of ulcer recurrence is
portrayed in Fig. Only the two studies where the GSV alone
was treated (Zamboni and ESCHAR) showed a significant
reduction in ulcer recurrence for the surgical arm.
DISCUSSION
The basis for the surgical approach: the Boston sur-
geon, John Homans, formulated our modern concept of
venous pathophysiology nearly a century ago and empha-
sized the role of ICPVs in the production of superficial
venous hypertension.1 Homans’ surgical plan for venous
Fig. Individual risk ratios for the four Randomized Controlled
Trials. The black blocks and their horizontal lines depict the risk
ratios (RR) of treatment failures and their respective 95% confi-
dence intervals (CI). The vertical line in the center of the figure
represents the RR of 1, where there is no difference in the outcome
between the surgical and compression groups. A, None of the
three trials show any advantage for surgery over conservative
treatment in ulcer healing. A confidence interval that crosses this
no-difference line indicates that the result of this study is not
statistically significant. B, The ESCHAR and Zamboni trials show
that surgery of the GSV reduces the incidence of ulcer recurrence,
but ICPV ligation does not-Dutch and Stacey trials.ulcer was based on eradication of both the GSV and partic-
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 4 O’Donnell et al 1047ularly the ICPVs.14 In 1938, Beecher, et al,15 as well as
Warren, et al,16 provided the hemodynamic basis of super-
ficial venous hypertension and its potential relationship
with venous ulcer. In his seminal article in 1938, Linton17
proposed a new surgical approach for ligating ICPVs
through a long medial calf incision and he stated, “It’s
necessary to interrupt communicating veins to affect a
cure”. The British surgeon, Frank Cockett, further refined
some of Linton’s concepts18 into what Cockett called the
“blow out theory”—an ulcer was the end result of a local
rise in venous pressure in the peri-ulcer area.19
Subfascial vein ligation of ICPVs through a longmedial
calf incision was the standard approach for venous ulcer as
typified by a leading 1970s article in the British Medical
Journal.20 “Venous ulcers could be treated by occluding
the incompetent connecting vein between the superficial
and deep system and so restore the pressure and flow to
normal.”20 This treatment was based on the concept that a
reduction in the abnormally elevated ambulatory superficial
venous pressure would, in turn, improve the abnormal
microcirculation. To examine whether surgical ablation of
ICPVs was associated with ulcer healing and prevention of
recurrence, we carried out several studies to test this hy-
pothesis. A 5-year retrospective follow-up study of ulcer
recurrence examined whether ligation of ICPVs was effec-
tive in preventing recurrence. In a review of 40 limbs 5 years
after ICPV ligation, 17 limbs with normal deep systems on
phlebography had only one ulcer recur (6%), while all 23
limbs with postthrombotic signs on phlebography devel-
oped an ulcer.21 In a subsequent prospective study of 109
limbs, 40 limbs with phlebographically-proven postthrom-
botic syndrome treatment of ICPVs and / GSV, did
not improve abnormal venous pressures.22 These two stud-
ies questioned the role of treating ICPVs in limbs with
postthrombotic deep venous incompetence.
Surgical options for incompetent perforating veins.
Due to the high wound morbidity rate (4-44%) of the open
approach combined with a significant recurrence of ulcers
(2-55%), however, the open surgical treatment fell in pop-
ularity and use.3 Several technical modifications were de-
veloped to minimize wound morbidity associated with
subfascial ligation, which included placement of the inci-
sion away from the compromised skin and subcutaneous
tissue to over the posterior calf—“the posterior stocking
seam approach.”23
Minimally invasive approach. Hauer modified avail-
able endoscopic techniques to ligate ICPVs through a
remote entry site on the upper medial calf using conven-
tional instruments (mediastinoscope and liga-clips).24 In
1991, we developed a laparoscopic closed approach, which
employed micro instruments and visualization of the oper-
ative field on a video screen.25,26 Both Glovicski27 and
Conrad28 independently modified the laparoscopic tech-
nique with a tourniquet and CO2insufflation. The closed
CO2 technique expanded the operating space and allowed
the surgeon to visualize, dissect, and clip the ICPVs.
Evidence for SEPS’ Efficacy. Ruckley stated that,
“Evidence-based medicine has not been so far a strongfeature of phlebological practice” and that appears to be
true for the data supporting SEPS.29 Levels of evidence and
the strength can be divided into those which address single
trials or those that are based on a compilation of trials-
systematic reviews and Meta analysis. Single studies of
therapy range from level 5, uncontrolled case series, with
weak statistical power to a level 1 study, a large RCT with a
low risk of error or bias and greater statistical strength.30
Even higher levels of evidence can be provided by system-
atic analyses of multiple studies and include the Cochrane
Systematic Reviews, AHRQ evidence reports, and a stan-
dard systematic review. Level 1 evidence is important be-
cause it provides scientific validation of a treatment option
and is statistically powerful. In addition, Center for Medi-
care Services (CMS) and other third party payors are
strongly influenced on a decision to reimburse for a therapy
by such data.8
While study design is an important component which
determines the validity of a trial, the choice of appropriate
outcomes is also essential. Unfortunately, many venous
series report hemodynamic outcomes, such as valve closure
times or air plethysmographic values, which are surrogate
outcomes of lower evidentiary power. By contrast, the
objective clinical outcomes specific for venous therapy in-
clude the Venous Clinical Severity Score,31 while self-
reported QOL assessments, such as the SF 36, address
global quality outcomes. Finally, there are venous-specific
QOL assessment tools such as the Aberdeen Varicose Vein
Score.32 Outcome measurements appear more straightfor-
ward for the evaluation of treatment options for C5/C6
disease where ulcer healing and ulcer recurrence help to
define the critical outcomes of treatment. Both outcomes
define critical elements of the disease process and are capa-
ble of change while being reproducible. Finally, the “qual-
ity” of a trial can be rated based on established criteria.5
This assessment is formalized in the GRADE recommen-
dations for therapy, where the strength of the recommen-
dation is “graded” on a scale from A-strong recommenda-
tion to C- weak recommendation.33
The evidence. The sequence of proof that the treat-
ment of ICPVs is important in ulcer healing and prevention
of ulcer recurrence depends on four statements:
PRO
(1) The treatment of ICPVs “cures” ulcers by promot-
ing healing and reducing recurrence.
(2) The treatment of ICPVs improves venous hemody-
namics (less powerful than # 1, because surrogate outcome
employed).
CON
(3) The treatment of the GSV alone cures ulcers by
promoting healing and reducing recurrence.
(4) The treatment of the GSV alone improves perfora-
tor function (less powerful than #3).
When is a perforating vein incompetent? The crite-
ria for determining by duplex scan whether a perforating
vein is incompetent is essential for judging not only if GSV
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portantly if the perforator actually is incompetent prior to
any form of surgery. As Stuart stated, “there is no standard
examination in the literature” for the duplex determination
of perforator competence.34 Themajority of the studies use
outward flow through the perforating vein with calf com-
pression, which exceeds 0.5 seconds as the criterion for
incompetence. By contrast, other studies also include the
diameter of the perforating vein as an added criterion.
Compelling information is scant to truly validate an out-
ward “reflux” of 0.5 seconds as the correct criterion for
perforator incompetence. Criteria for diagnostic tests need
to be compared to an independent “Gold Standard” that
declares the presence or absence of disease. The gold stan-
dard is essential to determine if the diagnostic study and
that diagnostic test’s particular threshold value for “disease
present” is adequately sensitive and specific.35 Ideally, var-
ious threshold values for a diagnostic study are applied in a
receiver operator curve format, so that a particular test value
can be assessed for its balance between sensitivity and
specificity. In a carefully designed and unique study
Yamamoto and associates36 examined the value of reflux
times and vein diameters in the detection of perforator
incompetence. In 304 legs, 324 perforators were identified
and imaged by duplex scanning. Incompetence was deter-
mined surgically by the Turner-Warwick bleed-back test
(bleeding from the divided end of the perforator on calf
compression). The criterion of duplex-determined reflux
0.5 seconds had a sensitivity of 87.7% and a specificity of
75.3%, when compared to the gold standard. True incom-
petent perforators had a diameter of 3.59/ 0.94 mms,
while true competent perforators had a diameter of 2.61
/ 0.91 mms—a difference in diameters of 1 mm. The
authors concluded that the sensitivity of reflux times was
not sufficient to determine perforator incompetence. A
second study by Sandri, et al,37 which did not use the gold
standard of back-bleeding from the divided perforator, but
did correlate perforator diameter with reflux, as indicated
by an outward reflux time of 0.05 seconds for perforator
incompetence. A vein diameter greater than 3.5 mms had a
positive predictive value of 90%, while a diameter less than
2.2 mm predicted lack of reflux in 92% of perforators.
These findings show how critical the values are for calling a
perforator incompetent. If the diagnostic criteria are strin-
gent, fewer perforators appear incompetent. Alternatively,
if the criteria are more liberal or several criteria are used to
declare incompetence more perforators may be declared
incompetent.
The four RCTs in this review varied in their criteria for
determining perforator incompetence. Stacey, et al9 em-
ployed the invasive technique of ascending phlebography,
which is a highly specific test for ICPVs, while the Dutch
SEPS trial11 cited retrograde flow of more than 0.5 seconds
after calf compression or valsalva as diagnostic for reflux.
The ESCHAR trial12 considered “relaxed flow of more
than 1 second clinically significant”. By contrast, Zamboni,
et al10 provided no data on the detection of calf perforators.
For the studies which assessed whether treatment of theGSV alone corrected perforator incompetence, the criteria
for perforator incompetence ranged from a simple finding
of “outward flow” to more strict criteria of an increased
perforator diameter3mmAND reversed or outward flow
0.5 seconds. Certainly it is difficult to compare one study
to another due to the varied definitions of perforator in-
competence, and this introduces a major problem in a
comprehensive analysis.
The treatment of ICPVs “cures” ulcers by promot-
ing healing and reducing recurrence. There are numer-
ous clinical studies (Case Series), which provide level V
evidence on the role of ICPV ligation in promoting ulcer
healing and reducing recurrence. As an example, our own
series of 42 limbs treated with SEPS showed a reduced ulcer
recurrence rate of approximately 12%.38 A larger series of
135 limbs, which comprised the North American SEPS
Registry, showed a higher ulcer recurrence rate.39 This
registry reaffirmed the concept that limbs with postthrom-
botic deep venous valvular involvement sustained an ele-
vated rate of ulcer recurrence (46%) in comparison to
primary valvular incompetence (20%).
Since no RCTs addressed the role of SEPS, several years
ago we performed a systematic review of the role of SEPS
for venous ulcers in order to reduce the high variance and
high uncertainty found in a simple compilation of several
small non-RCTs.6 This review identified one small RCT,
but this trial focused on wound morbidity, not ulcer heal-
ing/recurrence as an outcome.40 Twenty-two case series,
which yielded 1220 limbs for analysis, were identified in
our review. To reduce bias, our systematic review used
special statistical methods, such as a random effects model
and the Q-statistic test for heterogeneity. Ulcer healing
averaged 90% overall, while recurrence of venous ulcers was
6% for CEAPClass V (previously healed ulcers) and 11% for
class VI (open ulcers). These analyses showed that SEPS
was safe–complications were low with an infection rate
averaging 5%, neurologic complications 5%, and DVT 1%.
No deaths or perioperative pulmonary emboli occurred.
Since there was no comparator group (non-surgical treat-
ment), this meta analysis examined only one side of the
treatment options for venous ulcer. Moreover, bias was
inevitable, despite the use of statistical modifications. Thus,
the question of SEPS’ efficacy needs to be answered by
reviewing the results of the four RCTs.
The effect of ICPV ligation on ulcer heal-
ing/recurrence. The first RCT by Stacey,9 which com-
pared superficial venous surgery (subfascial ligation /
GSV treatment) to elastic compression, employed a surro-
gate outcome–hemodynamics rather than a clinical one.9
Little difference was noted. Ulcer recurrence was men-
tioned only in passing in the patient characteristics’ section,
risk ratio analysis demonstrated no difference in the reduc-
tion in ulcer recurrence (Fig).
The large level I RCT, the Dutch Ulcer trial,11 showed
no difference between the two groups for the primary
outcome, ulcer-free survival, but only for “stratified” sub-
sets. Unfortunately, this trial had several problems. The
major drawback was related to concomitant treatment of
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which blurs a clear interpretation of the role of SEPS alone.
Like other previous studies, this RCT actually examines
whether the surgical reduction of superficial venous hyper-
tension is superior to compression in the prevention of
ulcer recurrence. In addition, there was uneven recruitment
of subjects at the various centers with the majority of
patients (65%) treated at one of the 12 centers. The authors
stated that patients fared better at this high volume center,
which raised the question that the surgeons with more
experience with a new technique at that center obtained
better results than surgeons at other centers in the trial.
This is a common problem in surgical trials where the
surgical learning curve for a specialized technique may be
shorter and results better at a high volume center, even if
the surgical and comparator groups are randomized within
that center. This factor may have biased the trial.41 More-
over, the primary outcome was neither ulcer healing nor
recurrence, but rather ulcer-free survival. When ulcer heal-
ing was examined there was no difference between the
compression group 73%, or the surgical group 83%. Recur-
rence was also comparable between the two groups, being
23% in the compression group and 22% in the surgical
group, as emphasized in Fig. This later result “surprised”
the investigators, which they ascribed to quality issues in
the surgical arm—suggestive of the specialized center effect
and procedural learning curve.41 The ideal study should
limit treatment to ICPVs only or compare treatment of the
GSV in one arm to treatment of the GSV and ICPVs in the
other arm.
The treatment of ICPVs improves venous hemody-
namics (indirect evidence on the results of treating
ICPVs). There are several available studies which examine
the effect of treating ICPVs alone, but these detail hemo-
dynamic or surrogate outcomes. Unfortunately, these he-
modynamic outcome measures rather than clinical ones
reduce the quality of evidence by at least one level.
Bjordal42 carried out a unique study where blood flow and
venous pressure were measured following sequential occlu-
sion of either the GSV or ICPVs. Occlusion of the ICPV
reduced flow and pressure but did not return these values to
normal. Akesson, et al43 examined the effect of sequential
ligation of either the GSV or ICPVs in an interesting study
design. All limbs had recurrent venous ulceration and 85%
had phlebographically-proven deep venous disease. The
initial GSV surgery decreased the abnormal ambulatory
venous pressure, but ICPV ligation 3 months later pro-
duced no further reduction in ambulatory venous pressure.
Two RCTs with an appropriate study design, which
compared GSV ablation alone to a group with GSV abla-
tion and SEPS, were carried out with surrogate outcomes.
Fitredge, et al44 observed no differences in air plethysmo-
graphic parameters between the two groups. The authors
concluded that there was no support for routine treatment
of ICPVs. Kianifard, et al45 assessed QOL as well as the
number of post-op ICPVs and showed minimal differences
for the former and as expected fewer ICPVs for the ICPV-
treated group at 12 months. Unfortunately, the studypopulation like Fitridge’s study was composed of patients
with predominantly CEAP C2, mild disease.
The treatment of the great saphenous vein (GSV)
alone “cures” ulcers by promoting healing and reduc-
ing recurrence. Examining the effect of treatment of the
GSV alone in patients with advanced CVI where the clinical
outcomes of ulcer healing and ulcer recurrence were used as
outcomes can provide further critical evidence on the ne-
cessity for treating ICPVs. Zamboni, et al10 RCT compared
CHIVA (no direct treatment of ICPVs) to compression,
and surgery improved the proportion of healed ulcers and
their recurrence (Fig). The most provocative evidence that
questions the belief that ICPV ablation is required in the
management of venous ulcer arises from the ESCHAR
trial.12 The study clearly demonstrated a two-fold reduc-
tion in ulcer recurrence with GSV ablation over compres-
sion as shown in Fig.
The influence of deep venous incompetence in the
ESCHAR trial. Previous studies suggested that the status
of the deep system was an important factor in determining
the outcomes of superficial venous surgery for venous ulcer,
so that the ESCHAR trial stratified their patient population
by the status of these systems. Ulcer recurrence in the
superficial disease alone limbs averaged 12% in the surgical
arm vs 26% in the compression arm (P  .001). Superficial
venous incompetence and limited segmental deep disease
(76 limbs) showed similar advantages in the reduction of
ulcer recurrence for the surgical group (9%) vs 25% for the
compression group (P  .04). By contrast, those patients
with superficial venous disease and total deep venous in-
volvement showed no difference in the incidence of recur-
rent ulcer between the surgically-treated group and the
compression-treated group.
To address the short follow-up for ulcer recurrence (14
months mean) in the initial report from the ESCHAR trial,
which may underestimate the actual incidence, the investi-
gators recently reassessed their results with a longer mean
follow-up period of 3 years.13 The 3-year ulcer-healing rate
was 89% for the compression group and a near identical
93% in the surgically-treated group. The 4-year ulcer recur-
rence rate had crept up in both groups to 56% for the
compression group, but the surgical group’s recurrence
rate (31%) was still significantly less (P  .01). The rela-
tionship of ulcer recurrence to the status of the deep system
paralleled the earlier findings. Most importantly, the num-
ber of ulcer episodes was halved from 81 in the compression
group to 41 in the surgical group. These long-term results
show the clear superiority of GSV treatment for preventing
recurrence of venous ulcers in the absence of multi-level
deep venous reflux.
The treatment of the GSV alone improves perfora-
tor function. Following GSV ablation, Stuart’s duplex
scan study demonstrated a reduction in the number of all
ICPVs from 65% of limbs preoperatively to 37% postoper-
atively (P  .01).34 Other studies by Mendes, et al46 and
Blumgren, et al47 showed a reduction from nearly 90% of
limbs with ICPVs in both studies preoperatively to 30%
postoperatively (the former) and 40% (the later). In the
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following treatment increased from 45% to 49% in the
compression group, while ICPVs in the surgical group
reduced from 51% to 42%.48 These studies suggest that
treatment of the GSV alone directly affects the competence
of perforating veins.
Review of RCTs comparing surgery to compression
and wound care. The Figure presents a forest plot of the
four RCTs, which compare surgery to compression in the
management of chronic venous insufficiency CEAP C5/6
with the outcomes of ulcer healing and ulcer recurrence.
The four studies comprise two different surgical treatments
vs conservative therapy: (1) ligation and stripping of the
GSV (or GSV focused therapy) ESCHAR and Zamboni
and (2) ablation of ICPVs (majority had concomitant or
previous treatment of the GSV) Stacey9 and the van Gent,
et al,11 SEPS trial. In the assessment of benefit, none of
these studies showed an improvement in ulcer healing with
surgery over conservative therapy (compression and wound
care), as shown in FigA. The Barwell12 and Zamboni, et al,
studies10 clearly show a reduction in the risk of recurrent
ulcer, while both the Van Gent, et al,11 and Stacey9 studies
(ICPV treatment/ GSV) showed no significant reduc-
tion in the risk of ulcer recurrence or benefit (Fig B). In
assessing study quality, there are marked differences in both
study design and outcomes among the four studies, as
shown in Table I. The level II study of Stacey lacks many of
the appropriate design elements and clinical outcomes of a
proper study and is limited by the small number of subjects,
which predisposes to bias. Zamboni et al’s single center
RCT employs a unique surgical procedure, CHIVA that is
intended to reduce superficial venous hypertension, with-
out directly treating the ICPVs. This approach does intro-
duce two different surgical procedures: ligation of the GSV
or ligation of the GSV branches. This trial also apparently
Table II. Assessment of RCT study quality and harm of t
Element Stacey
Quality
Number 41 (limbs)
Multi-center NO N
A priori calculation NO Y
Concealment NO Y
Baseline comparability YES Y
Intention to treat NO N
Reason & number of drop outs NONE Y
Blinding NO N
Primary outcome Hemodynamics R
Length of follow-up (months) 12
Overall quality C B
Harm or risk
Mortality N.R.
Morbidity N.R. N
Hospital admission
Wound/bandages
DVT
N.R., Not reported; QOL, quality of life.
From reference #6 on SEPS.lacked an intention to treat (ITT) principle. The Dutchstudy had more subtle flaws (biases) in design and out-
comes as discussed previously, which limits its power. Het-
erogeneity, as produced by the different forms of surgical
treatment (combining GSV and ICPV treatment without
separate analysis, as occurred in the Stacey trial and the
Dutch trial or alternatively the two types of GSV treatment
in the Zamboni study)mars the analysis of these three trials.
Finally, the ESCHAR study has adhered to a strict study
design and has addressed one potential drawback–a rela-
tively short follow-up period by publishing an updated
summary extended out to 3 years, but without a change in
overall interpretation. The “quality” of the studies is rated
in Table II. The four studies were analyzed for safety (risk),
but only the ESCHAR RCT reported mortality and mor-
bidity. There were no deaths in either arm and there was no
difference in the number of subsequent hospitalizations
between the two arms.
Alternative treatments for incompetent perforating
veins. Ultrasound-guided sclerotherapy (UGS) and per-
cutaneous thermal ablations of ICPVs under ultrasound
guidance are two techniques that have been proposed for
the treatment of ICPVs. In 80 limbs that underwent UGS
of ICPVs, Masuda, et al,49 demonstrated that treatment
initially obliterated 95% of the ICPVs, but at 20months the
proportion of occluded ICPVs had decreased by 20% to
75%—C6 disease was a dominant factor for recurrence.
Elias and Peden50 have reviewed the results of several small
series of endovenous thermal ablation of ICPVs—the ma-
jority with short-term follow-up, surrogate outcomes, and
few C5/6 limbs.
CONCLUSION
The ESCHAR trial establishes a 1A recommendation
that ligation and stripping of the GSV is associated with the
prevention of ulcer recurrence. At present, there is no
ent of venous ulcer
mboni Dutch Barwell
47 200 500
YES YES
YES YES
YES YES
YES YES
YES YES
NONE YES
NO NO
ence, QOL Ulcer-free period Healing/recurrence
36 29 24/12
B A
0 0
N.R.
Cons. 1.5% surg 0.1%
5% Cons. 1.5% surg 1.3%
1% 0 0reatm
Za
O
ES
ES
ES
O
ES
O
ecurr
.R.compelling level 1 evidence to provide a grade A recom-
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nous ulcer healing or recurrence. The two studies do not
provide data on morbidity to assess risk while the benefit of
reducing ulcer recurrence is unsubstantiated (Fig B). Un-
fortunately, the treatment of ICPVs is blurred by concom-
itant treatment of GSV incompetence in the two RCTs that
putatively explored the role of ICPV treatment. Moreover,
surrogate hemodynamic outcomes, which assess the treat-
ment of ICPVs alone as well as the effect of GSV treatment
alone on perforator competence, also argue against the
importance of treating ICPVs. This observation underlines
the need for a properly designed trial in CEAP C5/6
patients. The trial design of Kianifard and Fitridge, where
patients are allocated to treatment of the GSV alone or
treatment of the GSV and ICPVs with the primary outcome
of ulcer healing and recurrence would be appropriate. The
results in limbs with deep venous incompetence or as an
additive effect to prevent recurrence in all limbs would be
important. Based on the RCTs cited and the results of
studies with surrogate endpoints of restoring perforator
competence, the current role of ICPV treatment can be
graded as a 2B recommendation. The clarity of benefit is
unclear from the RCTs and the methodological quality has
important limitations, which place this recommendation in
this category. The future role of ICPV ablation may be either
for limbs with total deep venous reflux or for improving the
results of patients treated with GSV ablation alone, but these
roles await a properly conducted RCT.
The author is grateful to Joseph Lau, MD, for his
critical analysis of the manuscript.
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